BioSpace News Archive

Korro Bio, Inc. presented new data for KRRO-110 and reported progress across its RNA editing portfolio at the J.P. Morgan Healthcare Conference on January 9, 2024.

Enigma Biomedical Group - USA (EBG-USA) today announced it has signed an exclusive license and option agreement with AbbVie for the development and potential commercialization of AbbVie’s next-generation F18 PET imaging biomarkers to assess the presence of four-repeat (4R) tau protein in patients with suspected neurodegenerative disease.

Credence MedSystems announced that it has successfully completed Factory Acceptance Testing for production of its Companion® injection device platform on the Company’s new Clinical Assembly Line.

Nectero Medical today announced initiation of a Phase II/III clinical trial (stAAAble) to investigate the safety and efficacy of the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System in patients with infrarenal abdominal aortic aneurysms (AAAs), maximum diameter 3.5 – 5.0cm.

Kallisio, focused on developing solutions to manage toxicity in cancer care, announces FDA 510(k) clearance for Stentra, an individually tailored 3D printed oral stent solution designed to protect healthy tissue in Head and Neck Cancer (HNC) patients.

iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will be participating in the Maxim Group Virtual Healthcare IT Conference on January 25, 2024.

Alaya.bio, a biotechnology company developing a novel polymeric delivery platform towards in situ cell therapies, announces a collaboration with CAR-T pioneer Michel Sadelain, MD, PhD, Stephen and Barbara Friedman Chair and Director, Center for Cell Engineering at the Memorial Sloan Kettering Cancer Center (MSK) in New York City.

Natera, Inc. announced that new data on its personalized and tumor-informed molecular residual disease test, Signatera™, will be presented at the American Society of Clinical Oncology’s 2024 Gastrointestinal Cancers Symposium, taking place January 18 – 20, 2024 in San Francisco, California.

Coya Therapeutics, Inc. announces that Howard Berman, Ph.D., Chief Executive Officer and Chairman of Coya Therapeutics, Arun Swaminathan, Ph.D., Chief Business Officer, and Fred Grossman DO, President and Chief Medical Officer, have been invited to participate in Chardan Capital Market’s upcoming biotechnology Leadership Call Series on Tuesday, January 30, 2024 at 10:30am ET.

ELIQUENT Life Sciences, a global regulatory consulting firm for the life sciences industry, announced the acquisition of RApport Global Strategic Services.